GlassScriptPhysician profile
John Mark Provenza
NPI 1225028434
$8,678.38
in general payments reported to CMS, 2019-2025
33 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,061 · 2021: $1,499 · 2022: $1,462 · 2023: $1,419 · 2024: $1,356 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.03 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,650.34 | 2019-2024 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $1,122.59 | 2019-2025 | |
| Janssen Biotech, INC. | $944.47 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $751.22 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $394.35 | 2022-2025 | |
| Daiichi Sankyo INC. | $352.62 | 2019-2024 | Injectafer |
| Celgene Corporation | $332.39 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $316.93 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $83.49 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $82.61 | 2023-2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $81.07 | 2023 | Zeposia |
| Redhill Biopharma INC. | $70.95 | 2020-2022 | |
| Ucb, INC. | $69.79 | 2019 | |
| Gilead Sciences, INC. | $62.32 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $56.60 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $56.20 | 2020-2024 | Ocaliva |
| Cumberland Pharmaceuticals, INC. | $46.99 | 2019 | |
| Amgen INC. | $42.92 | 2020-2021 | |
| Allergan, INC. | $42.87 | 2019 | |
| Qol Medical, LLC | $40.32 | 2023 | Sucraid |
| Evoke Pharma, INC. | $35.32 | 2021-2022 | |
| Novo Nordisk INC | $34.40 | 2023-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $33.40 | 2023 | Andexxa |
| Braintree Laboratories, INC. | $29.52 | 2020-2021 | |
| Lilly USA, LLC | $29.45 | 2024 | Omvoh |
| Medtronic, INC. | $27.41 | 2021 | |
| Ethicon US, LLC | $26.68 | 2022 | |
| Sandoz INC. | $20.42 | 2023 | Hyrimoz |
| Shire North American Group INC | $18.86 | 2019 | |
| Celltrion USA INC. | $17.24 | 2024 | Vegzelma |
| Amag Pharmaceuticals, INC. | $17.09 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Provenza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.